drugset
drugset / Trial / NCT03427788

BAY2328065 Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Relative Bioavailability, Food Effect

NCT03427788 ↗

Phase 1 Completed 72 enrolled Bayer
RandomizedParallel-groupQuadruple-blindBasic science

Summary

This single center, double-blind, randomized study with up to 11 treatment groups evaluates the safety and tolerability, pharmacokinetics, relative bioavailability and food effect of single ascending doses of BAY2328065

Timeline

Start
2018-03-21
Primary completion
2018-10-29
Completion
2019-02-11

Drugs

EvaluationDrugModalityDoseRoute
Subject BAY2328065 Unknown 2.25 mg Oral
Subject BAY2328065 Unknown 700 mg Oral

Indications

endometriosis